Prospective Randomized Trial of Irritative Symptoms Severity Assessment After (HoLEP) Versus ThuFLEP (PRISSA)

I.M. Sechenov First Moscow State Medical University

Status: Unknown

Conditions: Prostate Obstruction; BPH

Treatments: Procedure: Holmium laser enucleation of the prostate; Procedure: Thulium fiber laser enucleation of the prostate

Study type: Interventional

Funder types: Other

Identifiers

NCT04342533

Sechenov-Ho_Vs_TFL-20

Details and patient eligibility

About

The investigators hypothesize that the functional outcomes of both techniques are comparable. However, ThuFLEP might increase speed recovery of postoperative irritation and early stress urinary incontinence according to the Questionnaire for Urinary Incontinence Diagnosis (QUID) because of minimal tissue penetration depth of TFL.

Full description

Thulium fiber laser enucleation of the prostate (ThuFLEP) has already shown the outcomes comparable to OSP with better safety profile (lower blood loss compared to OSP) and shorter hospital stay. TFL has the efficacy and safety proven in comparative trials, being a promising rival for HoLEP. The main features of TFL distinguishing it from Ho:YAG is its wavelength of 1.94 µm (leading to about three-fold increase in water absorption and lesser penetration depth of <0.1 mm vs >0.2 mm in Ho:YAG). With identical average and peak powers of 100 W, the laser does not burst tissues, allowing for clean and precise cutting instead. Conversely, Ho:YAG's average power is about 100 W and its presumable peak power is around 10-15 kW. With such an outburst of energy, each pulse of Ho:YAG creates a large vapor bubble which ruptures the tissue. This may be a possible reason for increased irritative symptoms in early postoperative period after HoLEP comparing to ThuFLEP. But all in all, the probable causes for such postoperative symptoms remain unclear so far, despite the fact that absence of irritation and incontinence is ought to be one quality marker of "Pentafecta". According to the idea of high-power impact, probably, decreasing of HoLEP power will mitigate these problems. On the one hand, low-power HoLEP is feasible, safe and effective modality for symptomatic BPO. However, the results remain controversial and there is lack of LP-HoLEP application data nowadays. May be, with another option, for instance OSP or monopolar enucleation, it is possible to solve the issues. But the discussion of the past years demonstrates that the presence of early SUI is not only a problem of EEP, but also underreported in other approaches in relieving BPO secondary to BPH.

Enrollment: 140 estimated patients

Sex: Male

Volunteers: No Healthy Volunteers

Inclusion criteria

• LUTS presence, proven by:

  1. IPSS questionnaire (Score >20);
  2. OR uroflowmetry result (Qmax <10 ml/s);

Exclusion criteria

• Prostate volume > 120 cc
• Prostate cancer on pathology;
• Urethral strictures;
• Bladder calculi;
• Prior prostate surgery;
• Neurogenic bladder dysfunction.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Single Blind

---

140 participants in 2 patient groups

ThuFLEP

Experimental group

Description:

Patients who underwent thulium fiber enucleation of the prostate

Treatment:

Procedure: Thulium fiber laser enucleation of the prostate

HoLEP

Active Comparator group

Description:

Patients who underwent holmium laser enucleation of the prostate

Treatment:

Procedure: Holmium laser enucleation of the prostate